



(12) Translation of
European patent specification

(11) NO/EP 2595485 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/454 (2006.01)
A61P 25/18 (2006.01)
A61P 25/24 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.05.30
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.03.16
(86)	European Application Nr.	11810350.6
(86)	European Filing Date	2011.07.20
(87)	The European Application's Publication Date	2013.05.29
(30)	Priority	2010.07.20, US, 366080 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Minerva Neurosciences, Inc., 1601 Trapelo Road, Suite 286, Waltham, MA 02451, USA
(72)	Inventor	LUTHRINGER, Remy, Henri, Rue Etienne-dumont 18, 1204 Geneve, Sveits PELLEGRINI, Lorenzo, 1418 Ridgewood Lane, Newtown, PA 18940, USA KARABELAS, Argeris, N., 461 Court Street, Portsmouth, NH 03801, USA
(74)	Agent or Attorney	RWS, Europa House, Chiltern Park, Chiltern Hill, SL99FG CHALFONT ST PETER, Storbritannia


(54)	Title	METHODS OF USE CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR-MEDIATED DISORDERS
------	-------	---

(56)	References Cited:	US-B2- 7 166 617 EP-A1- 1 260 512 BENTHAM SCIENCE PUBLISHER BENTHAM SCIENCE PUBLISHER: "Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals", CURRENT PHARMACEUTICAL DESIGN, vol. 12, no. 30, 1 October 2006 (2006-10-01), pages 3857-3876, XP055107718, ISSN: 1381-6128, DOI: 10.2174/138161206778559614 anonymous: "View of NCT00861796 on 2009_03_12", ClinicalTrials.gov archive , 12 March 2009 (2009-03-12), XP007922577, Retrieved from the Internet: URL: http://clinicaltrials.gov/archive/NCT00861796/2009_03_12 [retrieved on 2014-03-13] KAY S R ET AL: "THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FOR SCHIZOPHRENIA", SCHIZOPHRENIA BULL, OXFORD UNIVERSITY PRESS, vol. 13, no. 2, 1 January 1987 (1987-01-01), pages 261-276, XP009020866, ISSN: 0586-7614 MARDER ET AL.: 'Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.' SCHIZOPHRENIA RESEARCH vol. 61, no. IS.2-3, 01 June 2003, pages 123 - 136, XP055105227
------	-------------------	--

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse på formelen (II) eller et farmasøytisk akseptabelt salt, hydrat eller solvat av dette,



til bruk i behandling av schizoaffectiv lidelse, eller i behandling eller lindring av minst ett symptom på schizoaffectiv lidelse hos et individ som lider av schizoaffectiv lidelse.

2. Forbindelse, salt, solvat eller hydrat til bruk ifølge krav 1, der forbindelsen er et hydrokloridsalt.

3. Forbindelse, salt, solvat eller hydrat til bruk ifølge krav 1 eller 2, der symptomet er problemer med å utføre oppgaver.

4. Forbindelse, salt, solvat eller hydrat til bruk ifølge krav 1 eller 2, der symptomet er dystymi.

5. Forbindelse, salt, solvat eller hydrat til bruk ifølge et av kravene 1–4, der minst to symptomer blir behandlet.